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Abstract: Lowering elevated blood pressure (BP) with drug therapy reduces the risk for 
catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. 
Given the heterogeneity of hypertension as a disease, the marked variability in an individual 
patient’s BP response, and low response rates with monotherapy, expert groups such as the Joint 
National Committee (JNC) emphasize the value of combination antihypertensive regimens, 
noting that combinations, usually of different classes, have additive antihypertensive effects. 
Metoprolol succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptor-blocking 
agent formulated to provide controlled and predictable release of metoprolol. Hydrochlorothia-
zide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis 
by acting on the distal renal tubule. The pharmacokinetics, efﬁ  cacy, and safety/tolerability of 
the antihypertensive combination tablet, metoprolol extended release hydrochlorothiazide, 
essentially reﬂ  ect the well-described independent characteristics of each of the component 
agents. Not only is the combination product more effective than monotherapy with the individual 
components but the combination product allows a low-dose multidrug regimen as an alternative 
to high-dose monotherapy, thereby, minimizing the likelihood of dose-related side-effects. 
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By treating hypertensive patients with metoprolol succinate extended release in 
combination with hydrochlorothiazide (metoprolol ER/HCT), the prescribing physician 
can expect additive antihypertensive effects. As will be illustrated in this review, 
the pharmacokinetics, safety, and tolerability of this antihypertensive combination 
essentially reﬂ  ect the well-described independent characteristics of each of the 
component agents.
Background
For over a decade, developed counties have been facing a persistent cardiovascular 
public health dilemma – a substantial proportion of hypertensives remain unaware of 
their elevated blood pressure and of those diagnosed, many are not treated to optimal, 
cardiovascular risk lowering target blood pressure levels (Hajjar and Kotchen 2003; 
JNC-7 2003).  Repeatedly, treatment guidelines and clinical trials underscore the fact 
that many patients require a multi-drug regimen (ALLHAT 2002; European Society 
of Hypertension 2003; JNC-7 2003; WHO 2003; Mourad et al 2004). Expert panels 
such as the Joint National Committee point out that when used in combination, an-
tihypertensive drugs additively lower blood pressure and can often do so employing 
low doses of the individual agents, thereby minimizing dose-related adverse effects 
(JNC-7 2003; Oﬁ  li 2006). Furthermore, many antihypertensive agents complement the 
actions of others, particularly when they are of different classes, eg, calcium channel 
blockers (CCBs) and beta-blockers; and, some combinations exhibit an off-setting Vascular Health and Risk Management 2007:3(3) 280
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impact on adverse effects, eg, diuretic vs angiotensin re-
ceptor blocker effects on serum potassium (JNC-7 2003). 
Combination antihypertensive regimens can also “override” 
population-speciﬁ  c effects. For example, while Blacks tend 
to respond to renin-angiotensin system (RAS) blockade to a 
lesser degree than Whites, both Blacks and Whites respond 
equally well to diuretic/RAS inhibitor combinations (Holland 
and Fairchild 1982; Hawkins et al 1988; The Association 
of Black Cardiologists (ABC) Candesartan Study Group 
2000; Papademetriou et al 2000). Moreover, the likelihood 
that a patient with more severely elevated blood pressure 
(>20/10 mmHg above goal) will attain goal with single agent 
treatment is so low that JNC-7 suggests initiating antihyper-
tensive treatment for these patients with a drug-combination. 
The JNC panel also notes that combining anti-hypertensive 
drugs into a single ﬁ  xed combination tablet can simplify 
multi-drug treatment regimens, an important consideration 
to facilitate patient compliance, and that ﬁ  xed combinations 
can also be less expensive (JNC-7 2003).
Encouragingly, in recent years there has been some im-
provement in hypertension control rates and this has been 
paralleled by an increased reliance upon combination therapy. 
Using the National Health and Nutrition Examination Survey 
(NHANES), Gu et al (2006) reported that during the years 
1999–2002, 62.9% of US hypertensive adults took a prescrip-
tion antihypertensive medication, compared with 57.3% for 
the years 1988–1994. During this same time period, multiple 
drug use increased from 29.1% to 35.8%. Of those patients 
on multiple drug treatment, about one-fourth were taking a 
diuretic/beta-blocker combination and about one-fourth a 
diuretic/angiotensin converting enzyme inhibitor (ACEI) 
combination, while somewhat lesser proportions were taking 
other combinations (diuretics/CCBs, beta-blockers/CCBs, 
ACEIs/CCBs, etc.) (Gu et al 2006). The relatively popular 
use of a diuretic/beta-blocker combination is not too surpris-
ing given the established beneﬁ  t of thiazides in averting the 
cardiovascular complications of hypertension and the poten-
tial beneﬁ  t of including a beta blocker in antihypertensive 
regimens for patients with important comorbid illnesses such 
as coronary artery disease (ALLHAT 2002; JNC-7 2003; 
Psaty et al 2003; Turnbull et al 2003).
Formulation
Metoprolol is a beta-1 (cardioselective) adrenoreceptor-
blocking agent. It was ﬁ  rst introduced as a tartrate salt and 
had pharmacokinetic/pharmacodynamic properties that 
necessitated twice- to thrice-daily dosing. This formulation 
is commonly referred to as “immediate release”. Metopro-
lol was subsequently formulated as an extended release 
tablet (metoprolol ER) using the succinate salt such that 95 
mg is equivalent to 100 mg of the metoprolol tartrate salt 
(TOPROL-XL® 2005; Sandberg et al 1988). This formula-
tion difference resulting in different pharmacokinetic and 
pharmacodynamic characteristics and dosing regimens is an 
important distinction, as many research reports fail to specify 
the metoprolol formulation studied; approved indications 
for the formulations differ in some countries and clinical 
study ﬁ  ndings have differed, depending on the formulation 
(TOPROL-XL® 2005).
The metoprolol ER properties are achieved by encapsula-
tion of the succinate salt with a polymeric coating to form 
micro-beads, which are then embedded in a tablet matrix. 
In the gastrointestinal tract the beads are released from the 
matrix and each bead, upon exposure to ﬂ  uid, allows outward 
diffusion of metoprolol over a period of about 20 hours (Plo-
sker and Clissold 1992; Sandberg et al 1988; TOPROL-XL® 
2005). Hydrochlorothiazide is a thiazide diuretic, typically 
available as a tablet formulation (Beermann et al 1976). By 
modifying the matrix of the metoprolol ER tablet to incorpo-
rate HCT it has been possible to develop a ﬁ  xed combination 
tablet that allows immediate release of HCT from the matrix 
while retaining the extended release properties for metoprolol 
(data on ﬁ  le; Sunzel Study D4026C00005 2004).
Pharmacokinetic/pharmacodynamic 
properties
The metoprolol ER/HCT ﬁ  xed combination tablet proved bio-
equivalent to the concomitant administration of the individual 
agents in single dose, cross-over studies at both metoprolol 
ER/HCT; 23.75/6.25 mg (low dose) and 95/12.5 mg (high 
dose) based both on Cmax and AUC (90% conﬁ  dence intervals 
for the ratios within 80%–125%) (data on ﬁ  le: Sunzel Study 
D4026C00006 2005; Sunzel Study D4026C00005 2004). 
The high dose study was conducted with subjects fasting and 
fed; the pharmacokinetic parameters were nearly identical 
under both conditions (Figures 1 and 2). The ﬁ  xed tablet 
bioequivalence with concomitantly administered components 
was conﬁ  rmed in a multiple dose (once daily for 5 days) 
study with a 100/12.5 mg tablet (data on ﬁ  le: Abrahamsson 
and Häggström Study 895 1987). In addition, the absence 
of a metoprolol/HCT pharmacokinetic interaction was 
demonstrated in a multiple dose study in which a 50/12.5 
mg tablet was compared with each component administered 
individually, a ﬁ  nding that was consistent with older stud-
ies conducted with metoprolol tartrate (Jordo et al 1979). 
Relative to immediate release metoprolol, the extended Vascular Health and Risk Management 2007:3(3) 281
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release formulation gives plasma metoprolol concentrations 
that tend to be smoother, exhibiting less peak-to-trough 
variation. This is reﬂ  ected in less variability in inhibition 
of exercise-induced increase in heart rate, a measure of 
beta-1 blockade (Darmansjah et al 1990; Sandberg et al 
1990; Polsker and Clissold 1992). These extended release 
properties are maintained in the combination as illustrated 
by a study that compared the metoprolol ER/HCT combina-
tion with an immediate release combination (100/12.5 mg), 
ie, there was less peak to trough variability in metoprolol 
plasma levels with the extended release combination and the 
extended release formulation elicited a smoother and more 
sustained beta-blockade over the inter-dosing interval (90% 
conﬁ  dence interval for the ratio of the area under the 24 hour 
effect curve: 105%–129%) (data on ﬁ  le: Abrahamsson and 















































Figure 1 Mean metoprolol plasma concentration versus time curve after administration of the ﬁ  xed combination tablet and the free combination of metoprolol succinate 















































Figure 2 Mean HCT plasma concentration versus time curve after administration of the ﬁ  xed combination tablet and the free combination of metoprolol succinate 
ER (1 × 95 mg) and HCT (1 × 12.5 mg) in a fasting (n = 48) and fed state (ﬁ  xed; n = 48, free; n = 47): Study D4026C00005.Vascular Health and Risk Management 2007:3(3) 282
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Antihypertensive effects
Although ﬁ  rst introduced as a ﬁ  xed combination tablet 
of 100/12.5 mg (metoprolol succinate ER/HCT) in 1989 
(Denmark), the antihypertensive activity of the combina-
tion over a wide dose range was only subsequently detailed 
in the Assessment of Toprol-XL Taken in Combination 
with Hydrochlorothiazide (ATTACH) trial. This was a US 
multicenter, randomized, double-blind, placebo-controlled, 
parallel group, unbalanced factorial study of 3 dose levels of 
hydrochlorothiazide (6.25, 12.5, and 25 mg), 4 dose levels 
of metoprolol ER (25, 50, 100, and 200 mg), and 9 of the 12 
potential combinations (metoprolol ER/HCT: 200/6.25 mg, 
25/25 mg, and 50/25 mg were not included). The design was 
structured to test the hypothesis that at least 1 metoprolol 
ER/HCT combination was superior to its components with 
regard to change from baseline in trough (24 hours post 
dosing) sitting diastolic blood pressure (SiDBP). The study 
enrolled men and women 18–80 years of age with SiDBP 
95–114 mmHg and SiSBP <180 mm Hg (following a placebo 
run-in period). 
The trial randomized a total of 1571 patients and met its 
primary objective, illustrating that the combination repre-
sented contributions from both components for both SiDBP 
and SiSBP, ie, the antihypertensive effects were additive. 
Blood pressure declined with the combination in a dose-
related fashion as it did with the component agents and these 
declines were well described, ﬁ  tted to quadratic regression 
dose-response surface models (Figure 3 and Figure 4). The 
model-derived, placebo-corrected reductions with blood 
pressure ranged from (SiSBP/SiDBP) 5.5/3.3 mmHg to 
14.7/10.4 mmHg for the combinations (Table 1). As is also 
apparent in Table 1, blood pressure reductions achieved with 
the highest doses of the individual agents can be attained 
with much lower doses in combination, eg, metoprolol ER 
50/HCT 6.25 mg or 12.5 mg (Papademetriou et al 2006).
When translated into hypertension control rates (<140/90 
mmHg or 130/80 mmHg if diabetic) the combination ren-
dered 31%–65% (based on dose) of patients controlled. The 
highest control rates attainable with the monotherapies at 
their highest doses were 38% for HCT and 47% for meto-
prolol ER. It is noted that about half the patients entered the 
trial with a baseline blood pressure >20/10 mmHg above their 
JNC goal (<140/90 mmHg or 130/80 mmHg if diabetic) and 























Figure 3 Dose response surface from polynomial regression of changes from baseline to week 8/LOCF in trough sitting diastolic blood pressure (intent-to-treat 
population) (ATTACH Trial). 
Note: Pyramids represent the treatment group mean values. Upward pyramids are above the surface, and downward pyramids are below the surface. Lines connect the 
pyramids with the corresponding ﬁ  tted value on the regression surface.
Regression equation: DBP: y = −5.34392 −0.06023*Toprol-XL −0.34772*HCT + 0.00015*Toprol-XL2 + 0.00703*HCT2.
Reprinted with permission from Papademetriou V, Hainer JW, Sugg J, et al, and ATTACH Study Group. 2006. Factorial antihypertensive study of an extended-release meto-
prolol and hydrochlorothiazide combination.  Am J Hypertens, 19:1217–25. Copyright © 2006 American Journal of Hypertension, Ltd.Vascular Health and Risk Management 2007:3(3) 283
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their goal with a combination regimen (Papademetriou et al 
2006).
Subgroup analyses in ATTACH based on age (65 vs 
<65 years), sex, and ethnicity (Blacks vs others) identiﬁ  ed 
little difference in overall antihypertensive responsiveness. 
Consistent with other reports, in ATTACH Blacks tended 
to respond to a lesser degree to metoprolol ER, and their 
response to diuretics was more pronounced, so that the 
combination was effective in both ethnic groups (Holland 
and Fairchild 1982; Hawkins et al 1988; Papademetriou 
et al 2006).
In ATTACH all patients received treatment as “initial” 
therapy. The effect of the metoprolol ER/HCT combina-
tion employed as an “add-on” treatment was evaluated in a 
smaller (n = 47) study of patients who remained hypertensive 
in spite of receiving HCT 12.5 mg per day. In this crossover 
study once daily metoprolol ER/HCT 100/12.5 mg was 
compared with an older metoprolol tartrate/HCT combina-
tion tablet. Blood pressure declined by approximately 10/10 
mmHg with the metoprolol ER combination and 8/8 mmHg 
with the tartrate combination (differences not statistically 

























Figure 4 Dose response surface from polynomial regression of changes from baseline to Week 8/LOCF in trough sitting diastolic blood pressure (intent-to-treat 
population) (ATTACH Trial).
Note: Pyramids represent the treatment group mean values. Upward pyramids are above the surface, and downward pyramids are below the surface. Lines connect the 
pyramids with the corresponding ﬁ  tted value on the regression surface. 
Regression equation: SBP: y = −4.20691 −0.08645*Toprol-XL −0.63844*HCT + 0.00026*Toprol-XL2 + 0.01324*HCT2.
Reprinted with permission from Papademetriou V, Hainer JW, Sugg J, et al, and ATTACH Study Group. 2006. Factorial antihypertensive study of an extended-release 
metoprolol and hydrochlorothiazide combination. Am J Hypertens, 19:1217–25. Copyright © 2006 American Journal of Hypertension, Ltd.
Table 1 Placebo-corrected predicted valuesa for change from baseline in SBP/DBP
TOPROL-XL® dosage
HCT  0 mg  25 mg  50 mg  100 mg  200 mg
dosage SBP/DBP  SBP/DBP  SBP/DBP  SBP/DBP  SBP/DBP
0  mg  0/0  –2.0/–1.4 –3.7/–2.6 –6.1/–4.5  –7.0/–6.1
6.25  mg  –3.5/–1.9  –5.5/–3.3 –7.2/–4.5 –9.6/–6.4  –10.5/–8.0b
12.5  mg  –5.9/–3.3  –7.9/–4.7 –9.6/–5.9 –12.0/–7.8  –12.9/–9.3
25 mg  –7.7/–4.3  –9.7/–5.7b –11.4/–6.9b –13.8/–8.8  –14.7/–10.4
aPredicted values from a least-squares quadratic regression model.
bThese doses were not studied.
Abbreviations: HCT, hydrochlorothiazide; SBP/DBP, systolic blood pressure/diastolic blood pressure. Vascular Health and Risk Management 2007:3(3) 284
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In addition to these controlled clinical trials, a number 
of large clinical experience trials evaluated metoprolol ER 
in combination with HCT (Table 2). Furthermore, 2 large 
hypertension clinical outcome trials (HOT and STOP-
hypertension 2) allowed for the use of metoprolol ER in com-
bination with diuretics (Table 3). In general, the experience 
described in these programs is consistent with the ﬁ  ndings 
in the ATTACH trial and support the use of diuretic/beta-
blocker combination treatment to avert the cardiovascular 
consequences of hypertension.
Safety and tolerability
From a safety/tolerability perspective, prescribing physicians 
should view metoprolol ER/HCT as “inheriting” all the 
potential safety/tolerability characteristics of the individual 
agents, including the admonition (“black box warning”) that 
abrupt cessation of beta-blocker therapy can exacerbate an-
gina pectoris or even precipitate acute myocardial infarction 
(TOPROL-XL® 2005). A key question for the combination 
is whether there are any safety/tolerability ﬁ  ndings that are 
either unique to the combination or which represent an ad-
ditive effect. Examples might include fatigue or metabolic 
abnormalities, both of which are common to each component 
agent. In the ATTACH trial of 1564 patients, the incidence 
of fatigue was 2.6% with metoprolol ER/HCT (across all 
doses) compared with 0.7% with placebo but at the highest 
dose (200/25 mg; metoprolol ER/HCT) the rate was 10.2% 
which compared with 2.0% and 6.3% for the individual 
agents, implying a possible additive effect for fatigue with 
high dose combinations. Relative to placebo, the rates for 
other common adverse effects were low: nasopharyngitis 
(3.4% vs 1.3%), dizziness (2.6% vs 2.6%), and nausea 
(1.4% vs 0.7%); adverse event discontinuation rates were 
2.7% and 2.6% for combination and placebo, respectively 
(Papademetriou et al 2006).
The effects of thiazide diuretics and beta-blocking agents 
on glucose metabolism are also well described and the 
metoprolol ER/HCT combination would also be expected 
to induce similar metabolic effects (Dornhorst et al 1985; 
Samuelsson et al 1994; HydroDiuril 1998; TOPROL-XL® 
2005). With regard to metoprolol, the large GEMENI trial 
noted an increase in hemoglobin A1C with immediate release 
metoprolol tartrate relative to the alpha-beta blocking drug, 
carvedilol in hypertensive type II diabetic patients already 
receiving a RAS blocking agent (ACE inhibitor or ARB). At 
the end of the trial, over 40% of the patients in both treatment 
groups were also receiving a thiazide diuretic (Bakris et al 
2004). While the ATTACH trial noted no change in fasting 
glucose levels with metoprolol ER/HCT, the study was not of 
adequate size to critically assess an impact on glucose control 
in patients with diabetes as only 10% of the study subjects 
were diabetic (Papademetriou et al 2006). Falkner et al looked 
speciﬁ  cally at insulin sensitivity (insulin clamp method) and 
found that metoprolol ER did not alter insulin sensitivity 
when added to HCT treatment in hypertensive patients. On 
average, the patients were already “insulin resistant” prior to 
adding metoprolol ER (Falkner et al 2006). She repeated the 
experiment in hypertensive patients who also had diabetes 
but, again, found that metoprolol ER did not signiﬁ  cantly 
alter insulin sensitivity (Falkner B pers comm 2007).
As one would expect, serum potassium declined with 
metoprolol ER/HCT in the ATTACH trial but somewhat less 
so than with HCT mono-therapy, perhaps attributable to renin-
inhibition consequences of beta-adrenergic blockade (Figure 5) 
(Papademetriou et al 2006). Also as expected, the ATTACH 


























































Figure 5 Potassium values: mean change from baseline to Visit 8 (safety population) (ATTACH Trial).Vascular Health and Risk Management 2007:3(3) 285
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Table 2 Clinical studies of metoprolol/hydrochlorothiazide combination tablets
Reference Study design/population Number of 
patients
Principal ﬁ  ndings
Hildemann et al 2002 Prospective, open-label, 8-week, 
observational study/hypertensive 
adults
14,964 Mean BP reduction from baseline to week 8 was 24.5/13.6 mmHg. 
The reduction in BP was consistent whether or not patients were 
receiving other antihypertensive drugs, which included ACEIs, al-
dosterone antagonists, alpha-blockers, other beta-blockers, calcium 
antagonists, and other diuretics. Tolerability was excellent.
Geisler 1981 Open-label study in patients treated 
with metoprolol/HCT 100/12.5 mg, 
1–2 tablets daily for 6 weeks/hyper-
tensive patients.
12,336 BP was signiﬁ  cantly reduced across all age groups in this large 
patient population. SBP decreased by 29–30 mmHg and DBP by 
13–15 mmHg after 6 weeks treatment. The incidence of AEs was 
low and similar in all age groups.
Goodfellow and 
Westberg 1981
Post-marketing surveillance for 3 
months of hypertensive patients in 
general practice. 
Treatment: metoprolol/HCT
100/12.5 mg, 1–2 tablets daily
1,446 After 3 months treatment mean BP was reduced from 181/108 
mmHg to 153/91mmHg. Previously untreated patients showed a 
more marked reduction in BP (33/20 mmHg) than patients previ-
ously treated (23/15 mmHg). All age groups showed a similar re-
duction in SBP and DBP although older patients had a higher BP on 
entry. The incidence of AEs was similar in all age groups. Treatment 
was withdrawn in 117 patients due to AEs. The rate of withdrawal 
was somewhat higher in patients aged over 65 years. Conclusion: 
The ﬁ  xed dose combination of HCT and metoprolol constitutes a 
simple once daily regimen, which is effective, produces few side-ef-
fects and is well tolerated by patients of all ages.
LaPalio et al 1992 Prospective, open-label surveil-
lance study. Multicenter outpatient. 
Patients with mild to moderate 
hypertension aged 50–75 years. 
Patients were treated with 100 
mg of metoprolol once daily for 4 
weeks. If BP was controlled, therapy 
continued. If not controlled, 25 mg 





After 4 weeks of therapy, mean SBP and DBP decreased from 
162/95 to 148/87 mmHg (p < 0.001). 58% of the patients had 
satisfactory BP control.  At 4 weeks 28% were requested to add 
HCT 25 mg to metoprolol 100 mg. At the end of 8 weeks, mean 
SBP and DBP decreased to 143/84 mmHg. BP response was similar 
in all age groups. At the termination of the study, 50% of the 
patients were continued on monotherapy, and 27% were continued 
on combined therapy. Overall, there was <5% incidence of medical 
problems, tolerability was good-excellent for 94% of the patients. 
Conclusion: Metoprolol administered as monotherapy or in com-
bination with HCT was effective in normalizing BP in a majority of 
elderly hypertensive patients. Both regimens were well tolerated.
Wikstrand et al 1986 Randomized, double-blind paral-
lel group study of patients with 
untreated essential hypertension. 
Patients were treated with either 
metoprolol 100 mg or HCT 25 
mg for 4 weeks. Patients with 
controlled DBP were treated for a 
further 4 weeks at the same doses. 
If DBP remained >95 mmHg then 
HCT 12.5 mg was added to meto-
prolol and HCT dose was doubled 




A signiﬁ  cant reduction in BP was recorded on both treatment regi-
mens. Both treatment regimens were well tolerated. The dropout 
rate due to serious side-effects was similar in the 2 groups, 2% 
in the metoprolol group and 3% in the HCT group. Conclusion: 
Beginning treatment with metoprolol 100 mg bd and adding HCT 
12.5 mg in patients not responding to metoprolol alone appears to 
be effective and safe in elderly hypertensive patients.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; BP, blood pressure; HCT, hydrochlorothiazide; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
AE adverse event. Vascular Health and Risk Management 2007:3(3) 286
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Table 3 Clinical outcome trials in support of safety and tolerability with combination treatment
Reference Study design Population and 
number of patients
Principal ﬁ  ndings
Dahlof et al 1991 This was a double-blind, multicenter, 
randomized study to compare antihy-
pertensive treatment with placebo. 
Initial drug therapy consisted of a 
once-daily diuretic (25 mg HCT 
and 2.5 mg of amiloride), a beta-
blocker (50 mg of atenolol, 100 mg of 
metoprolol succinate ER, or 5 mg of 
pindolol), or matching placebo after a 
1- to 6-month washout period. Active 
treatment drugs could be combined 
if BP exceeded 160/95 mmHg after 2 
months. For the placebo group, anti-
hypertensive therapy could be added 
if the BP exceeded 230/120 mmHg. 
The primary outcome was MI, stroke, 
and other CV death. 
Patients had a SBP between 180 
and 230 mmHg and a DBP of 90 
mmHg or higher, OR a DBP of 
105–129 mmHg. 
1627 patients aged 70–84 years
Average follow-up time was 25 months. 
At 12 months, the placebo-corrected changes 
in BP were greatest when the beta-blocker 
was combined with a diuretic.
Less than 1/3 of the active treatment patients 
were on monotherapy.
Treatment reduced total mortality by 43% 
(p = 0.0079) and strokes by 47% 
(p = 0.0081). The rate of all MIs was not 
reduced over this short duration of 
follow-up.
Hansson et al 1999 This was a double-blind, multicenter, 
randomized study to compare older 
antihypertensive agents with newer 
agents. 
1st group) Conventional treatment 
group, which consisted of once-daily 
diuretic, beta-blocker, or both: 50 mg 
of atenolol, 100 mg metoprolol 
succinate ER, 5 mg of pindolol, or 
the combination of 25 mg HCT and 
2.5 mg of amiloride, which could 
be combined with the beta-blocker 
monotherapy if the target BP of 
160/95 was not achieved.
2nd group) To achieve treatment 
goals, ACEI was supplemented with 
HCT.
3rd group) The calcium antagonists 
felodipine or isradipine were aug-
mented with any of the above beta-
blockers to achieve the target BP. 
The primary combined endpoint was 
fatal stroke, fatal MI, and other fatal 
CV diseases.
Patients had a SBP of 180 mmHg 
or higher, DBP was 105 mmHg 
or higher, or both. Patients with 
isolated systolic hypertension 
were also included. 
A total of 6614 patients aged 
70–84 years
- 2213 patients received conven-
tional treatment 
- 2205 received ACEI
- 2196 received a calcium antago-
nists
33,249 patient-years were ac-
cumulated
After 24 months, there was no difference 
in reduction of BP among the 3 treatment 
groups. 
After 60.3 months, there was no difference 
among the 3 groups for the primary end-
point of CV death. Major morbidity events 
were similar among the groups. The primary 
endpoint did not differ signiﬁ  cantly among 
the 719 diabetic elderly patients.
Combination therapy was used for 46% of 
patients.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HCT, hydrochlorothiazide; 
ER, extended release; CV, cardiovascular; MI, myocardial infarction.Vascular Health and Risk Management 2007:3(3) 287
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a small decline in mean HDL cholesterol. The combination 
treatments tended to reﬂ  ect the inﬂ  uence of the effects of the 
individual agents: there was a small increase in total choles-
terol with HCT as monotherapy and a small decline in total 
cholesterol with TOPROL-XL®, ie, no consistent change); 
and while generally small, the increases in triglyceride levels 
tended to be additive (Papademetriou et al 2006).
Dosing and administration
A combination metoprolol succinate ER/HCT tablet has 
been available in a number of countries (ﬁ  rst approved in 
Denmark in 1989) as Selocomb ZOK® prolonged release 
tablet. In the US the FDA granted approval for the combi-
nation on 28 August 2006 as Dutoprol® – indicated for the 
management of hypertension. The ﬁ  xed-dose combination 
is not indicated for initial therapy. The dosing and admin-
istration labeling cites the ﬁ  ndings from the ATTACH trial, 
noting that HCT was effective in doses of 6.25–25 mg and 
metoprolol ER in doses of 25–200 mg and recommends that 
dosing be individualized considering baseline and target 
blood pressure as well as experience with the individual 
agents. Dutoprol tablet strengths (metoprolol ER/HCT) are 
25/12.5 mg, 50/12.5 mg, and 100/12.5 mg, which can be 
divided to give half tablets of 50/6.25 mg (FDA website: 
http://clinicaltrials.gov).
Summary
Metoprolol succinate extended release/hydrochlorothiazide 
(metoprolol ER/HCT) tablets lower blood pressure in hy-
pertensive patients. The blood pressure reductions are dose 
related and represent additive antihypertensive contributions 
from the component agents. The likelihood of controlling el-
evated blood pressure with the combination product is greater 
than with the component agents employed as monotherapies, 
even in patients with more severe levels of hypertension. The 
combination also provides an option to treat with lower doses 
of the individual agents. Metoprolol ER/HCT is generally 
well tolerated, reﬂ  ecting the characteristics of the compo-
nents, but it also reﬂ  ects the same safety proﬁ  les including the 
admonition to avoid abrupt cessation of treatment in patients 
with or at risk for underlying coronary artery disease.
Physicians might also consider that low dose combination 
products provide an option to intervene with well-tolerated 
treatments early in the course of hypertension and might well 
help patients avert more intractable hypertension (Julius et 
al 2006). Certainly, this combination approach expands the 
population likely to respond to antihypertensive therapy 
compared with single agent treatment.
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